Pharmacovigilance challenges in Biosimilars


Same proportion pharmacovigilance for biosimilars has comparatively more different from other products. Biosimilars 2019 session mainly look that have already been announced to incorporate enhanced tracking and follow-up of post marketing surveillance issues, and on FDA initiative planned different changes in AERS, pilots of latest developed post market strategies of drug-monitoring and ADR related problems. the rules of biosimilars for pharmacovigilance and pharma epidemiology are the points that shall be laid emphasis within the session In USA average annual income mostly spend on biologics comparing to generic drugs for example:16% on biologics and three on other drugs.


  • Manufacturing methods
  • Product names
  • Generics and brand name products
  • Postapproval surveillance for immunogenicity
  • Evolving guidelines

Related Conference of Pharmacovigilance challenges in Biosimilars

July 27-28, 2026

19th World Drug Delivery Summit

Paris, France
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy
September 14-15, 2026

6th International Conference on Pharmaceutical Chemistry

Paris, France
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
December 14-15, 2026

5th Global Summit on Pharmaceutical Research

Paris, France
January 26-27, 2027

22nd Annual Meet on Pharmaceutical Sciences

Paris, France
April 27-28, 2027

10th European Biopharma Congress

Paris, France

Pharmacovigilance challenges in Biosimilars Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in